|
May 2
|
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
|
|
May 2
|
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
|
|
May 2
|
Q1 2024 Corcept Therapeutics Inc Earnings Call
|
|
May 2
|
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
|
|
Apr 30
|
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
|
|
Apr 22
|
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
|
|
Apr 21
|
11 Best Low Price Pharma Stocks To Invest In
|
|
Apr 19
|
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
|
|
Apr 18
|
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
|
|
Apr 16
|
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
|
|
Apr 16
|
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
|
|
Apr 15
|
Israeli economy has proven to thrive despite crisis: Expert
|
|
Apr 11
|
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
|
|
Apr 9
|
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
|
|
Apr 6
|
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
|
|
Apr 4
|
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
|
|
Apr 3
|
3 No-Brainer Stocks to Buy With $600 Right Now
|
|
Apr 3
|
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
|
|
Apr 1
|
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|